Spectrum Pharmaceuticals was acquired by Assertio Holdings, Inc. in an all-stock and contingent value rights transaction valued at approximately $250 million upfront. The strategic merger combined Spectrum's oncology commercial infrastructure and its flagship FDA-approved leukocyte growth factor treatment, Rolvedon, into Assertio's diversified pharmaceutical portfolio, transforming Spectrum into a wholly owned subsidiary of the acquiring corporation.